Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers

Basic and Clinical Pharmacology and Toxicology

Volumn 99, Issue 1, 2006, Pages 33-36

  Swart, Pieter J ^a   Krauwinkel, Walter J J ^a   Smulders, Ronald A ^a   Smith, Neila N ^b  

^a Astellas Pharma Global Development   (Netherlands)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; KETOCONAZOLE; SOLIFENACIN;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL LABORATORY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; MALE; NORMAL HUMAN; NOSE CONGESTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SORE THROAT; VITAL SIGN; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; TETRAHYDROISOQUINOLINES;

EID: 33745817847     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_285.x     Document Type: Article

References (13)

1. Chapple, C. R., P. Araño, J. L. H. R. Bosch, D. de Ridder, A. E. J. L. Kramer & A. M. Ridder: Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International 2004, 93, 71-77.
2. FDA Guidance for Industry page. In vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling. US Food and Drug Administration Web site. Available at: http://www.fda.gov/cber/gdlns/metabol.htm. Accessed February 26, 2003.
3. Gascoigne, E., W. Barton, G. J. Michaels, M. Meuldermans & W. Heykants: The kinetics of ketoconazole in animals and man. Clin. Res. Rev. 1981, 1, 177-187.
4. 3 receptor antagonism by the novel anti-muscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedeberg's Arch. Pharmacol. 2002, 366, 97-103.
5. Krauwinkel, W. J. J., R. A. Smulders, H. Mulder, P. J. Swart & M. E. Taekema-Roelvink: Effect of age on the pharmacokinetics of solifenacin in men and women. International Journal of Clinical Pharmacology & Therapeutics. 2005, 43, 227-238.
6. Kuipers, M. E, W. J. J. Krauwinkel, H. Mulder & N. Visser: Solifenacin demonstrates high absolute bioavailability in healthy men. Drugs in R&D 2004, 5, 73-81.
7. Physicians'desk reference: Nizoral® (ketoconazole) (prescribing information). Montvale: Thomson PDR, 2003, 1780-1782.
8. Smulders, R. A., W. J. J. Krauwinkel & J. van Zijtveld: Pharmacokinetics, pharmacodynamics, and safety of YM905 in healthy, elderly subjects. J. Amer. Geriat. Soc. 2003, 51, S101-S102.
9. Smulders, R. A., W. J. J. Krauwinkel, P. J. Swart & M. Huang: Pharmacokinetics and Safety of Solifenacin Succinate in Healthy Young Men. J. Clin. Pharmacol. 2004, 44, 1023-1033.
10. Uchida, T., W. J. J. Krauwinkel, H. Mulder & R. A. Smulders: Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. Brit. J. Clin. Pharmacol. 2004, 58, 4-7.
11. Venkatakrishnan, K., L. L. von Moltke & D. J. Greenblatt: Effects of the antifungal agents on oxidative drug metabolism. Clin. Pharmacokin. 2000, 38, 111-180.
12. Wienkers, L. C.: Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery. J. Pharmacol. Toxicol. Meth. 2001, 45, 79-84.
13. Yanagihara, T., Y. Kamiyama, T. Iwatsubo, K. Noguchi, H. Kamimura, R. Smolders & P. J. Swart: In vitro metabolism of a new anti-muscarinic agent solifenacin succinate in humans. Drug Metab. Rev. 2003, 35, 183.